Neurology 1999;52:1636
© 1999 American Academy of Neurology
Articles
Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b
C. Borràs, BS,
J. Río, MD,
J. Porcel, BS,
M. Barrios, BS,
M. Tintoré, MD and
X. Montalban, MD
From the Unit of Clinical Neuroimmunology, Hospital Vall d’Hebron, Barcelona, Spain.
Address correspondence and reprint requests to Cecília Borràs, Unit of Clinical Neuroimmunology, Escola d’Infermeria, 5a planta, Hospital Vall d’Hebron, Pssg, Vall d’Hebron, 119-129, 08035 Barcelona, Spain; e-mail: cborras{at}hg.vhebron.es
BACKGROUND: Depression has been cited as a possible side effect of interferon beta-1b (IFNß-1b) therapy in patients with MS. This association remains unproven because of a lack of longitudinal studies.
OBJECTIVE: To determine the changes in emotional state in relapsing-remitting (RR) MS patients during the first 2 years of treatment with IFNß-1b.
METHODS: Emotional state was evaluated in a sample of 90 patients at the onset of IFNß-1b treatment during an inclusion period of 2.5 years. Seventy-five patients were evaluated at their 12th month of treatment and 56 patients at their 24th month. We assessed their emotional state with the following psychological tests: Hamilton Depression Rating Scale, Beck Depression Inventory, and State-Trait Anxiety Inventory.
RESULTS: We found significant improvement in emotional state after the first and second years of treatment.
CONCLUSIONS: Our findings show that IFNß-1b does not increase depression or anxiety in RR MS patients during the first and second years of IFNß-1b treatment. In fact, slight but significant improvement in depression and anxiety symptoms was observed during this period.
This article has been cited by other articles:
|
|
|
|
 
S. Patten, J. Williams, and L. Metz
Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
Multiple Sclerosis,
April 1, 2008;
14(3):
406 - 411.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Cetin, K.L. Johnson, D.M. Ehde, C.M. Kuehn, D. Amtmann, and G.H. Kraft
Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample
Multiple Sclerosis,
September 1, 2007;
13(8):
1046 - 1053.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Porcel, J Rio, A Sanchez-Betancourt, M J Arevalo, M Tintore, N Tellez, C Borras, C Nos, and X Montalban
Long-term emotional state of multiple sclerosis patients treated with interferon beta
Multiple Sclerosis,
November 1, 2006;
12(6):
802 - 807.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P A Arnett and J J Randolph
Longitudinal course of depression symptoms in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
May 1, 2006;
77(5):
606 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Di Legge, M C Piattella, C Pozzilli, P Pantano, F Caramia, I F Pestalozza, A Paolillo, and G L Lenzi
Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis
Multiple Sclerosis,
June 1, 2003;
9(3):
302 - 306.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. J. Modrego, M.A. Pina, A. Simon, and M. C. Azuara
The Interrelations Between Disability and Quality of Life in Patients with Multiple Sclerosis in the Area of Bajo Aragon, Spain: A Geographically Based Survey
Neurorehabil Neural Repair,
January 1, 2001;
15(1):
69 - 73.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Feinstein
Multiple sclerosis, disease modifying treatments and depression: a critical methodological review
Multiple Sclerosis,
October 1, 2000;
6(5):
343 - 348.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. U. Walther and R. Hohlfeld
Multiple sclerosis: Side effects of interferon beta therapy and their management
Neurology,
November 1, 1999;
53(8):
1622 - 1622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
